Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel B Mark

Showing results (1-10 of 331) with videos related to

Pageof 34
Sort By:
Heart (British Cardiac Society)|September 25, 2007
Percutaneous coronary revascularisation: is it ever worth what it costs?Daniel B Mark
Journal of the American College of Cardiology|May 10, 2008
Interpreting the music of drug-eluting stents: halcyon song or albatross dirge?Daniel B Mark
Nature Reviews. Cardiology|February 19, 2016
Assessing quality-of-life outcomes in cardiovascular clinical researchDaniel B Mark
Journal of the American College of Cardiology|September 6, 2003
Clinical prediction models: are we building better mousetraps?Lawrence Liao, Daniel B Mark
Circulation|July 24, 2002
Medical economics and the assessment of value in cardiovascular medicine: Part IDaniel B Mark, Mark A Hlatky
Journal of the American College of Cardiology|February 11, 2026
Choosing Between CABG and PCI for 3-Vessel Coronary Disease: What's Cost Got to Do With It?Daniel B Mark, Sunil V Rao
JAMA|August 23, 2017
PCSK9 Inhibitors and the Choice Between Innovation, Efficiency, and AffordabilityDaniel B Mark, Kevin A Schulman
Circulation. Arrhythmia and Electrophysiology|June 17, 2016
Cost-Effectiveness of Left Atrial Appendage Occlusion: A Case Based on Facts Not in Evidence?Sean D Pokorney, Daniel B Mark
JACC. Heart Failure|November 2, 2015
When Business and Science Clash, How Can We Avoid Harming Patients?: The Case of AVOID-HFDaniel B Mark, Christopher M O'Connor
Journal of Cardiac Failure|September 19, 2003
Quality still doesn't pay in heart failure managementDavid J Whellan, Daniel B Mark
Pageof 34

Showing results (1-10 of 331) with videos related to

Sort By:
Pageof 34
Heart (British Cardiac Society)|September 25, 2007
Percutaneous coronary revascularisation: is it ever worth what it costs?Daniel B Mark
Journal of the American College of Cardiology|May 10, 2008
Interpreting the music of drug-eluting stents: halcyon song or albatross dirge?Daniel B Mark
Nature Reviews. Cardiology|February 19, 2016
Assessing quality-of-life outcomes in cardiovascular clinical researchDaniel B Mark
Journal of the American College of Cardiology|September 6, 2003
Clinical prediction models: are we building better mousetraps?Lawrence Liao, Daniel B Mark
Circulation|July 24, 2002
Medical economics and the assessment of value in cardiovascular medicine: Part IDaniel B Mark, Mark A Hlatky
Journal of the American College of Cardiology|February 11, 2026
Choosing Between CABG and PCI for 3-Vessel Coronary Disease: What's Cost Got to Do With It?Daniel B Mark, Sunil V Rao
JAMA|August 23, 2017
PCSK9 Inhibitors and the Choice Between Innovation, Efficiency, and AffordabilityDaniel B Mark, Kevin A Schulman
Circulation. Arrhythmia and Electrophysiology|June 17, 2016
Cost-Effectiveness of Left Atrial Appendage Occlusion: A Case Based on Facts Not in Evidence?Sean D Pokorney, Daniel B Mark
JACC. Heart Failure|November 2, 2015
When Business and Science Clash, How Can We Avoid Harming Patients?: The Case of AVOID-HFDaniel B Mark, Christopher M O'Connor
Journal of Cardiac Failure|September 19, 2003
Quality still doesn't pay in heart failure managementDavid J Whellan, Daniel B Mark
Pageof 34